DeECO

Reckitt Recalls Two Batches of Prosobee 12.9 oz Simply Plant Based Infant Formula Because of Possible Health Risk

By DeECO / February 22, 2023 / Comments Off on Reckitt Recalls Two Batches of Prosobee 12.9 oz Simply Plant Based Infant Formula Because of Possible Health Risk

Original Post Summary Company Announcement Date: February 20, 2023 FDA Publish Date: February 20, 2023 Product Type: Food & BeveragesInfant Formula & FoodsFoodborne Illness Reason for Announcement: Potential Cronobacter sakazakii contamination Company Name: Reckitt Brand Name: Enfamil ProSobee Product Description: Enfamil Prosobee Simply Plant-Based Infant Formula in 12.9 oz containers Company Announcement ‘The company has…

Read More

FDA Advances Additional Activities to Prevent Drug Overdoses and Reduce Death

By DeECO / February 21, 2023 / Comments Off on FDA Advances Additional Activities to Prevent Drug Overdoses and Reduce Death

Original Post For Immediate Release: February 16, 2023 Statement From: Robert M. Califf, M.D., MACCCommissioner of Food and Drugs – Food and Drug Administration Addressing the drug overdose crisis and substance use disorder (SUD) is an issue of great concern for our nation and remains a top public health priority for the U.S. Food and…

Read More

Infants at Risk for Aluminum Toxicity with Unapproved Potassium Phosphates Drug Product

By DeECO / February 13, 2023 / Comments Off on Infants at Risk for Aluminum Toxicity with Unapproved Potassium Phosphates Drug Product

Original Post FDA is warning health care professionals and pharmacies to avoid using Hospira’s unapproved potassium phosphates drug product in pediatric patients because the aluminum exposure from this product is unsafe for this population.   This product alone may produce daily aluminum exposures of up to twice the FDA-recommended limit for parenteral nutrition, with additional…

Read More

Universal Meditech Inc. Recalls Skippack Medical Lab COVID-19 Direct Antigen Rapid Tests That Are Not Authorized, Cleared, or Approved by the FDA

By DeECO / February 9, 2023 / Comments Off on Universal Meditech Inc. Recalls Skippack Medical Lab COVID-19 Direct Antigen Rapid Tests That Are Not Authorized, Cleared, or Approved by the FDA

Original Post The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. The devices described in this recall notice are the same devices announced in the FDA safety communication Do Not Use Skippack Medical Lab SARS-CoV-2 COVID-19 Tests. Recalled Product…

Read More

Access to Naloxone Can Save a Life During an Opioid Overdose

By DeECO / February 8, 2023 / Comments Off on Access to Naloxone Can Save a Life During an Opioid Overdose

Original Post Anyone can save a life during an opioid overdose with naloxone, a front-line defense in the nation’s opioid crisis. Naloxone is a life-saving drug that, when sprayed into the nose or injected, quickly reverses the powerful effects of opioids during an overdose. Everyone who overdoses with opioids, whether with a prescribed medicine or…

Read More

FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

By DeECO / February 7, 2023 / Comments Off on FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

Original Post For Immediate Release: February 01, 2023 Today, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. Jesduvroq is not approved for patients…

Read More

FDA announces Evusheld is not currently authorized for emergency use in the U.S.

By DeECO / January 30, 2023 / Comments Off on FDA announces Evusheld is not currently authorized for emergency use in the U.S.

Original Post FDA announces Evusheld is not currently authorized for emergency use in the U.S. Update [1/26/2023] The U.S. Food and Drug Administration today revised the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based…

Read More

FDA approves drug combination treatment for adults with asthma

By DeECO / January 17, 2023 / Comments Off on FDA approves drug combination treatment for adults with asthma

Original Post Action FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Airsupra is a combination of albuterol (a beta-2 adrenergic agonist) and budesonide (a corticosteroid). It is the first combination…

Read More

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment

By DeECO / January 9, 2023 / Comments Off on FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment

Original Post For Immediate Release: January 06, 2023 Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the…

Read More

Focusing on Prevention to Safeguard Infant Formula

By DeECO / November 17, 2022 / Comments Off on Focusing on Prevention to Safeguard Infant Formula

Original Post By: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Nutrition Over this last year, some families around our country faced challenges finding infant formula, a product that serves as the sole source of nutrition for many infants in the U.S. What started with reports of illnesses in infants led to a…

Read More